Strongbridge Biopharma plc to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Strongbridge Biopharma (Nasdaq: SBBP) has announced its virtual presentation at the Jefferies 2020 Healthcare Conference on June 4, 2020, at 4:30 p.m. ET. The event will focus on the company's commitment to developing therapies for rare diseases. The presentation will be accessible live and archived on their website's Investor section. Strongbridge's key products include RECORLEV, a cortisol synthesis inhibitor undergoing Phase 3 studies for Cushing’s syndrome, and KEVEYIS, the first FDA-approved treatment for certain periodic paralysis variants.

DUBLIN, Ireland and TREVOSE, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present virtually at the Jefferies 2020 Healthcare Conference on Thursday, June 4, at 4:30 p.m. ET.

The Company’s presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV^® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS^® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:

Investor Relations
Solebury Trout
Mike Biega
+1 617-221-9660
mbiega@soleburytrout.com

Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com

 

FAQ

When is Strongbridge Biopharma presenting at the Jefferies 2020 Healthcare Conference?

Strongbridge Biopharma will present virtually on June 4, 2020, at 4:30 p.m. ET.

Where can I watch Strongbridge Biopharma's presentation?

The presentation will be webcast live and archived on the Investor section of Strongbridge's website.

What is RECORLEV and its significance for Strongbridge Biopharma?

RECORLEV is a cortisol synthesis inhibitor in Phase 3 studies for Cushing’s syndrome and is part of Strongbridge's rare endocrine franchise.

What is KEVEYIS and its importance for Strongbridge?

KEVEYIS is the first FDA-approved treatment for hyperkalemic and hypokalemic periodic paralysis, demonstrating Strongbridge's focus on rare neuromuscular diseases.

Does Strongbridge Biopharma have any orphan drug designations?

Yes, both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency.